Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.35B | 1.32B | 1.26B | 1.30B | 1.20B | 1.10B |
Gross Profit | 508.87M | 482.95M | 441.07M | 437.73M | 432.73M | 410.57M |
EBITDA | 188.76M | 181.43M | 141.71M | 118.18M | 149.43M | -6.09M |
Net Income | 95.77M | 86.95M | 44.52M | 19.56M | 55.23M | -71.93M |
Balance Sheet | ||||||
Total Assets | 1.28B | 1.17B | 1.23B | 1.27B | 1.33B | 1.31B |
Cash, Cash Equivalents and Short-Term Investments | 121.70M | 99.23M | 110.50M | 97.56M | 97.25M | 103.05M |
Total Debt | 389.56M | 383.14M | 515.45M | 610.62M | 615.59M | 676.59M |
Total Liabilities | 703.20M | 681.67M | 804.15M | 904.97M | 966.66M | 979.47M |
Stockholders Equity | 1.28B | 489.15M | 425.95M | 361.54M | 363.40M | 326.54M |
Cash Flow | ||||||
Free Cash Flow | 121.14M | 114.64M | 115.93M | 24.62M | 58.62M | 56.12M |
Operating Cash Flow | 156.14M | 148.43M | 142.03M | 43.06M | 86.69M | 119.07M |
Investing Cash Flow | -33.63M | -30.37M | -19.51M | -18.44M | -28.07M | -61.69M |
Financing Cash Flow | -102.01M | -125.23M | -111.56M | -19.49M | -60.86M | -42.72M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | $1.57B | 16.49 | 18.63% | 0.15% | 6.26% | 44.74% | |
74 Outperform | $1.75B | 18.45 | 7.15% | ― | 4.05% | -47.49% | |
74 Outperform | $760.97M | 14.96 | 10.69% | 6.40% | -4.89% | -19.26% | |
64 Neutral | $1.49B | 16.77 | 9.09% | 2.33% | 2.18% | -22.35% | |
61 Neutral | $17.75B | 12.56 | -5.49% | 3.02% | 1.43% | -14.12% | |
58 Neutral | $1.46B | 45.68 | -2.77% | 3.49% | 1.14% | -149.26% | |
55 Neutral | $1.33B | 9.43 | 18.68% | 2.06% | -6.15% | ― |
On August 1, 2025, Interface, Inc. reported its second quarter results, showcasing an 8% increase in net sales to $376 million and a 45% rise in GAAP earnings per diluted share. The company’s ‘One Interface’ strategy has driven significant growth and profitability, particularly in the Americas, with notable market share gains. The strategy has resulted in a 28% increase in billings in the healthcare sector and a 403 basis point expansion in gross profit margin, highlighting the company’s strong market position and effective execution despite economic uncertainties.